ERIS

Eris Lifesciences Share Price

 

 

Invest in Eris Lifesciences with 3.32X leverage

Invest with MTF

Performance

  • Low
  • ₹1,622
  • High
  • ₹1,700
  • 52 Week Low
  • ₹1,097
  • 52 Week High
  • ₹1,910
  • Open Price₹1,700
  • Previous Close₹1,701
  • Volume250,499

Investment Returns

  • Over 1 Month + 2.87%
  • Over 3 Month -4.09%
  • Over 6 Month + 0.22%
  • Over 1 Year + 9.55%

Smart Investing Starts Here Start SIP with Eris Lifesciences for Steady Growth!

Invest Now

Eris Lifesciences Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 53.4
  • PEG Ratio
  • 2.8
  • Market Cap Cr
  • 22,205
  • P/B Ratio
  • Average True Range
  • 52.62
  • EPS
  • 30.52
  • Dividend Yield
  • 0.5
  • MACD Signal
  • -5.06
  • RSI
  • 64.4
  • MFI
  • 88.05

Eris Lifesciences Financials

Eris Lifesciences Technicals

EMA & SMA

Current Price
₹1,630.10
-71.2 (-4.19%)
pointer
  • Bearish Moving Average 2
  • Bullish Moving Average 14
  • 20 Day
  • ₹1,598.34
  • 50 Day
  • ₹1,612.19
  • 100 Day
  • ₹1,618.98
  • 200 Day
  • ₹1,563.06

Resistance and Support

1659.73 Pivot Speed
  • R3 1,983.67
  • R2 1,861.83
  • R1 1,781.57
  • S1 1,579.47
  • S2 1,457.63
  • S3 1,377.37

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Eris Lifesciences Ltd. is a leading Indian pharmaceutical company specializing in chronic and sub-chronic therapies. With 70% in-house manufacturing and a pan-India distribution network, Eris generates 86% of its revenue from chronic care, serving over 500,000 chemists nationwide.

Eris Lifesciences has an operating revenue of Rs. 2,998.16 Cr. on a trailing 12-month basis. An annual revenue growth of 43% is outstanding, Pre-tax margin of 17% is great, ROE of 12% is good. The company has a debt to equity of 61%, which is bit higher. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 76 which is a FAIR score but needs to improve its earnings, a RS Rating of 64 which is FAIR indicating the recent price performance, Buyer Demand at C+ which is evident from recent supply seen, Group Rank of 100 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of C is fair but needs to improve. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Eris Lifesciences Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-24 Preferential issue of shares Inter-alia, To consider the protposal of issuance ofequity shares of the Company by way of a preferential issue for consideration other than cash.. per share(601%)Interim Dividend
2025-11-12 Quarterly Results
2025-08-05 Quarterly Results
2025-05-19 Audited Results
2025-02-07 Interim Dividend
Date Purpose Remarks
2025-02-13 INTERIM Rs.7.35 per share(735%)Interim Dividend
2022-08-16 INTERIM Rs.7.35 per share(735%)Interim Dividend
2021-08-06 INTERIM Rs.6.01 per share(601%)Interim Dividend
View Eris Lifesciences Dividend History Arrow

Eris Lifesciences F&O

Eris Lifesciences Shareholding Pattern

54.85%
17.33%
1.2%
7.21%
0%
9.12%
10.29%

About Eris Lifesciences

  • NSE Symbol
  • ERIS
  • BSE Symbol
  • 540596
  • Chairperson & Managing Director
  • Mr. Amit Bakshi
  • ISIN
  • INE406M01024

Similar Stocks to Eris Lifesciences

Eris Lifesciences FAQs

Eris Lifesciences share price is ₹1,630 As on 10 December, 2025 | 10:35

The Market Cap of Eris Lifesciences is ₹22204.7 Cr As on 10 December, 2025 | 10:35

The P/E ratio of Eris Lifesciences is 53.4 As on 10 December, 2025 | 10:35

The PB ratio of Eris Lifesciences is 8 As on 10 December, 2025 | 10:35

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23